XBIO - Xenetic Biosciences
$1.15 -0.02 (-1.71%)Updated: 04:18 Jan 20, 2022 EST
$1.20 0.05 (4.35%)Premarket (Updated At 2022-01-20 09:18:25)
|Curr. Week||Curr. Month||Curr. Quarter||Next Quarter||Curr Year||-3.4||-0.85||-0.74||-0.77||-0.6|
CURRENT VOLATILITY RANK
Variation from the lowest to the highest value in a period.
|Curr. Week||Curr. Month||Curr. Quarter||Next Quarter||Curr Year||3.4||3.37||3.37||4.6||4.55|
The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.
|Curr. Week||Next Week||Curr. Month||Curr. Quarter||0%||0%||0%||0%|
MOVING AVERAGE METRIC
|5 Sessions||Change 5 Sessions||20 Sessions||Change 20 Sessions||50 Sessions||Change 50 Sessions||200 Sessions||1.27||-5.22%||1.34||-2.19%||1.37||-30.46%||1.97|
|RS Hour||RSI Hour||RS Day||RSI Day||N/A||N/A||N/A||N/A|
|F. Time Employees:||4|
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Xenetic Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.